How AI Is Reshaping Clinical Trial Intelligence in 2026

• Who are the fastest growing competitors?
• What are the areas of therapy that are becoming more competitive?
• What are the new indications that ought to get sponsored?
• Which trials are likely to be affected by delayed recruitment?
• What assets could be potential licenses?

The capabilities are transforming all aspects of clinical intelligence. The world's speediest analysis of worldwide clinical trials.

AI has the potential to gather, structure and analyse data from several trusted sources, and save hours of time in monitoring global research activity.

Intelligence teams can easily find:

• Newly initiated studies
• Trial completions
•  Phase transitions
• Geographic expansion
• Emerging sponsors

Changes in priority of development

This enables organizations to react quickly to shifts in the competitive environment.

Smarter Patient Recruitment and Site Selection

One of the most significant issues in clinical development is patient recruitment.

Modern AI models use the performance of enrollment in the past, the experience of investigators, patient demographics, disease prevalence, and site performance to suggest best research sites.

Industry analyses in recent years have indicated that AI-driven methods have the potential to enhance enrollment efficiency and provide live forecasts of recruitment, allowing for proactive steps to be taken.

The sponsors benefit from better site selection by: